We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Omalizumab in severe asthma and food allergies with IgE levels >1500 kU/L: Two‐year evaluation.
- Authors
Dinardo, Giulio; Cafarotti, Arianna; Galletta, Francesca; Fiocchi, Alessandro; Arasi, Stefania
- Abstract
This document discusses the potential benefits and safety of using omalizumab, a medication used to treat severe allergic asthma, in patients with high levels of serum total IgE (tIgE). The study found that omalizumab can reduce asthma exacerbations and improve lung function in patients with severe allergic asthma and tIgE levels between 1500 and 3300 kU/L. Additionally, the study suggests that omalizumab may have a protective effect and improve outcomes for patients with IgE-mediated food allergies. However, the study has limitations due to a small number of participants and the need for reliable biomarkers to determine the effectiveness of omalizumab. The authors also disclose their potential conflicts of interest.
- Subjects
FOOD allergy; IMMUNOGLOBULIN E; OMALIZUMAB; ASTHMA; ATOPY; CONFLICT of interests
- Publication
Pediatric Allergy & Immunology, 2023, Vol 34, Issue 12, p1
- ISSN
0905-6157
- Publication type
Article
- DOI
10.1111/pai.14057